ウーシー・バイオロジクス、シンガポールに新施設を開設しグローバルCDMOネットワークを拡充
WuXi Biologics' Singapore expansion reflects the growing importance of Southeast Asia as a biologics manufacturing hub.
WuXi Biologics announced a new state-of-the-art biologics manufacturing facility in Singapore, expanding its global CDMO network and strengthening antibody and cell therapy capabilities.
药明生物宣布扩展其全球合同开发与生产组织（CDMO）网络，在新加坡新建最先进的生物制品制造设施。该设施将作为公司东南亚和全球运营的关键枢纽，加强其在抗体和细胞治疗制造方面的能力。
WuXi Biologics' Singapore expansion reflects the growing importance of Southeast Asia as a biologics manufacturing hub. The move diversifies the company's geographic footprint beyond China amid ongoing geopolitical considerations around biotech supply chains.
Singapore emerging as APAC biologics manufacturing hub. WuXi's expansion diversifies China-centric biotech supply chains within APAC region.
Where this signal fits in the broader landscape.
https://www.wuxibiologics.com/news/singapore-facility-expansion-2026
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
ログイン